Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Leases (2020 - 2025)

Precision Biosciences (DTIL) has disclosed Current Leases for 6 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 14.17% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 14.17% year-over-year, with the annual reading at $1.5 million for FY2025, 14.17% up from the prior year.
  • Current Leases for Q4 2025 was $1.5 million at Precision Biosciences, up from $1.5 million in the prior quarter.
  • The five-year high for Current Leases was $2.5 million in Q2 2023, with the low at $1.1 million in Q4 2023.
  • Average Current Leases over 5 years is $1.7 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Current Leases rose 29.68% in 2023, then plummeted 51.06% in 2024.
  • Over 5 years, Current Leases stood at $1.8 million in 2021, then decreased by 7.9% to $1.7 million in 2022, then tumbled by 32.48% to $1.1 million in 2023, then grew by 16.5% to $1.3 million in 2024, then rose by 14.17% to $1.5 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $1.5 million, $1.5 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.